Cancer treatment has advanced dramatically in recent decades, yet relapse remains one of the most persistent challenges in oncology. Many patients complete surgery, chemotherapy, or radiation and are declared cancer-free—only to face the devastating return of disease years later. Researchers have long sought to understand why certain cancers come back stronger and more resistant than before.
A leading explanation lies in a small and elusive population of cells known as cancer stem cells. Unlike typical tumor cells, which rapidly divide and are vulnerable to chemotherapy, cancer stem cells behave in a more covert manner. They enter a dormant state within the body, allowing them to evade therapies designed to target fast-growing cells. These dormant cells can remain inactive for long periods before reawakening and initiating new tumor growth.
At Virginia Commonwealth University, Professor Umesh Desai has dedicated more than three decades to studying complex sugar-like molecules that may hold the key to overcoming this problem. His research centers on glycosaminoglycans (GAGs), long chains of natural sugars found on the surface of almost all human cells. GAGs play critical roles in cell communication, inflammation, blood clotting, and tissue growth, yet many of their functions in disease remain poorly understood.
Desai hypothesized that GAGs could serve as blueprints for new therapeutic compounds. Natural GAGs such as heparin are widely used as anticoagulants, but their variability and side effects have prompted interest in safer synthetic alternatives. Desai’s laboratory began producing synthetic molecules designed to mimic specific GAG structures with greater precision and consistency.
This work led to the development of a novel compound called G2.2, created in collaboration with Dr. Bhaumik Patel, a physician-scientist specializing in colorectal and gastrointestinal cancers. Desai likens cancer stem cells to hibernating bears—untouched by external threats while in their dormant state. Conventional treatments cannot effectively target this phase, but G2.2 disrupts the process.
G2.2 acts by interacting with a receptor on cancer stem cells, pushing them out of dormancy. Once activated, the cells are directed into a signaling pathway that triggers their destruction. In laboratory models, G2.2 eliminated dormant stem cells in colorectal cancer with striking efficiency. Encouragingly, similar effects were observed in models of lung, brain, kidney, and pancreatic tumors, suggesting broad therapeutic potential.
Another promising finding relates to safety and immunological impact. In preclinical studies, G2.2 did not produce major toxic side effects and appeared to stimulate T-cells, enhancing the body’s natural immune response against cancer.
Although G2.2 remains in the preclinical phase, it represents a significant shift in cancer research. Rather than focusing solely on proliferating tumor cells, this approach targets the underlying stem cell population that fuels relapse. If successful in future clinical development, it could become a strategy that prevents cancer from reemerging and improves long-term survival.